Advertisement
Screener

LISATA THERAPEUTICS, INC. (LSTA) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

LISATA THERAPEUTICS, INC. Research and Development Expense

LISATA THERAPEUTICS, INC. (LSTA) reported Research and Development Expense of $3.24 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-04

  • LISATA THERAPEUTICS, INC. research and development expense for the quarter ending 2022-06-30 was $3.24M, a 25.18% decline year-over-year.
  • LISATA THERAPEUTICS, INC. research and development expense for the quarter ending 2022-03-31 was $3.28M, a 35.42% decline year-over-year.
  • LISATA THERAPEUTICS, INC. research and development expense for the quarter ending 2021-12-31 was $4.15M, a 42.76% increase year-over-year.
  • LISATA THERAPEUTICS, INC. research and development expense for the quarter ending 2021-09-30 was $4.13M, a 36.18% increase year-over-year.
  • LISATA THERAPEUTICS, INC. research and development expense for fiscal 2021 was $17.68M, a 91.07% increase from fiscal 2020.
  • LISATA THERAPEUTICS, INC. research and development expense for fiscal 2020 was $9.25M, a 14.30% decline from fiscal 2019.
  • LISATA THERAPEUTICS, INC. research and development expense for fiscal 2019 was $10.80M, a 42.18% increase from fiscal 2018.
  • LISATA THERAPEUTICS, INC. research and development expense for fiscal 2018 was $7.59M, a 52.07% decline from fiscal 2017.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2022-06-30$3.24M
10-Q · filed 2022-08-04
$6.52M
10-Q · filed 2022-08-04
$10.67M
derived: sum of 3 quarters · filed 2022-08-04
$14.79M
derived: sum of 4 quarters · filed 2022-08-04
2022-03-31$3.28M
10-Q · filed 2022-05-05
$7.43M
derived: sum of 2 quarters · filed 2022-05-05
$11.55M
derived: sum of 3 quarters · filed 2022-05-05
$15.88M
derived: sum of 4 quarters · filed 2022-08-04
2021-12-31$4.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22
$8.28M
derived: sum of 2 quarters · filed 2022-03-22
$12.60M
derived: sum of 3 quarters · filed 2022-08-04
$17.68M
10-K · filed 2022-03-22
2021-09-30$4.13M
10-Q · filed 2021-11-04
$8.45M
derived: sum of 2 quarters · filed 2022-08-04
$13.53M
10-Q · filed 2021-11-04
$16.44M
derived: sum of 4 quarters · filed 2022-08-04
2021-06-30$4.33M
10-Q · filed 2022-08-04
$9.40M
10-Q · filed 2022-08-04
$12.31M
derived: sum of 3 quarters · filed 2022-08-04
$15.34M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$5.08M
10-Q · filed 2022-05-05
$7.98M
derived: sum of 2 quarters · filed 2022-05-05
$11.01M
derived: sum of 3 quarters · filed 2022-05-05
$12.83M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$2.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22
$5.94M
derived: sum of 2 quarters · filed 2022-03-22
$7.75M
derived: sum of 3 quarters · filed 2022-03-22
$9.25M
10-K · filed 2022-03-22
2020-09-30$3.03M
10-Q · filed 2021-11-04
$4.85M
derived: sum of 2 quarters · filed 2021-11-04
$6.35M
10-Q · filed 2021-11-04
$9.11M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$1.82M
10-Q · filed 2021-08-05
$3.32M
10-Q · filed 2021-08-05
$6.08M
derived: sum of 3 quarters · filed 2021-08-05
$9.09M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$1.50M
10-Q · filed 2021-05-06
$4.27M
derived: sum of 2 quarters · filed 2021-05-06
$7.27M
derived: sum of 3 quarters · filed 2021-05-06
$10.26M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$2.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$5.77M
derived: sum of 2 quarters · filed 2021-02-25
$8.76M
derived: sum of 3 quarters · filed 2021-02-25
$10.80M
10-K · filed 2021-02-25
2019-09-30$3.00M
10-Q · filed 2020-11-05
$5.99M
derived: sum of 2 quarters · filed 2020-11-05
$8.03M
10-Q · filed 2020-11-05
$9.54M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$2.99M
10-Q · filed 2020-08-13
$5.03M
10-Q · filed 2020-08-13
$6.53M
derived: sum of 3 quarters · filed 2020-08-13
$8.23M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31$2.04M
10-Q · filed 2020-05-07
$3.55M
derived: sum of 2 quarters · filed 2020-05-07
$5.25M
derived: sum of 3 quarters · filed 2020-05-07
$7.37M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$1.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05
$3.21M
derived: sum of 2 quarters · filed 2020-03-05
$5.33M
derived: sum of 3 quarters · filed 2020-03-05
$7.59M
10-K · filed 2020-03-05
2018-09-30$1.70M
10-Q · filed 2019-11-06
$1.70M
10-Q · filed 2018-11-08
$3.82M
derived: sum of 2 quarters · filed 2019-11-06
$6.09M
10-Q · filed 2019-11-06
$6.09M
10-Q · filed 2018-11-08
$10.74M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30$2.12M
10-Q · filed 2019-08-08
$2.12M
10-Q · filed 2018-08-09
$4.38M
10-Q · filed 2019-08-08
$4.38M
10-Q · filed 2018-08-09
$9.04M
derived: sum of 3 quarters · filed 2019-08-08
$12.22M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31$2.26M
10-Q · filed 2019-05-09
$2.26M
10-Q · filed 2018-05-10
$6.91M
derived: sum of 2 quarters · filed 2019-05-09
$10.10M
derived: sum of 3 quarters · filed 2019-05-09
$14.38M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$4.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14
$7.84M
derived: sum of 2 quarters · filed 2019-03-14
$12.12M
derived: sum of 3 quarters · filed 2019-03-14
$15.84M
10-K · filed 2019-03-14
$15.84M
10-K · filed 2018-03-22
2017-09-30$3.19M
10-Q · filed 2018-11-08
$7.46M
derived: sum of 2 quarters · filed 2018-11-08
$11.19M
10-Q · filed 2018-11-08
$14.39M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30$4.28M
10-Q · filed 2018-08-09
$8.00M
10-Q · filed 2018-08-09
$11.21M
derived: sum of 3 quarters · filed 2018-08-09
$14.17M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$3.73M
10-Q · filed 2018-05-10
$3.46M
10-Q · filed 2017-05-15
$6.93M
derived: sum of 2 quarters · filed 2018-05-10
$9.89M
derived: sum of 3 quarters · filed 2018-05-10
$14.38M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$3.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22
$6.16M
derived: sum of 2 quarters · filed 2018-03-22
$10.65M
derived: sum of 3 quarters · filed 2018-03-22
$16.70M
10-K · filed 2018-03-22
$15.11M
10-K · filed 2017-03-17
2016-09-30$2.96M
10-Q · filed 2017-11-09
$2.63M
10-Q · filed 2016-11-07
$7.45M
derived: sum of 2 quarters · filed 2017-11-09
$13.50M
10-Q · filed 2017-11-09
$12.53M
10-Q · filed 2016-11-07
$16.50M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$4.49M
10-Q · filed 2017-08-10
$4.03M
10-Q · filed 2016-08-09
$10.54M
10-Q · filed 2017-08-10
$9.90M
10-Q · filed 2016-08-09
$13.54M
derived: sum of 3 quarters · filed 2017-08-10
$19.86M
derived: sum of 4 quarters · filed 2017-08-10
2016-03-31$5.88M
10-Q · filed 2017-05-15
$9.06M
derived: sum of 2 quarters · filed 2017-05-15
$15.37M
derived: sum of 3 quarters · filed 2017-05-15
$22.97M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$3.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17
$9.49M
derived: sum of 2 quarters · filed 2017-03-17
$17.10M
derived: sum of 3 quarters · filed 2017-03-17
$23.90M
10-K · filed 2017-03-17
2015-09-30$6.32M
10-Q · filed 2016-11-07
$13.92M
derived: sum of 2 quarters · filed 2016-11-07
$20.72M
10-Q · filed 2016-11-07
$30.89M
derived: sum of 4 quarters · filed 2016-11-07
2015-06-30$7.60M
10-Q · filed 2016-08-09
$14.40M
10-Q · filed 2016-08-09
$24.57M
derived: sum of 3 quarters · filed 2016-08-09
$33.04M
derived: sum of 4 quarters · filed 2016-08-09
2015-03-31$6.80M
10-Q · filed 2016-05-05
$16.97M
derived: sum of 2 quarters · filed 2016-05-05
$25.44M
derived: sum of 3 quarters · filed 2016-05-05
$31.24M
derived: sum of 4 quarters · filed 2016-05-05
2014-12-31$10.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$18.64M
derived: sum of 2 quarters · filed 2016-03-15
$24.44M
derived: sum of 3 quarters · filed 2016-03-15
$29.19M
10-K · filed 2016-03-15
2014-09-30$8.47M
10-Q · filed 2015-11-05
$14.27M
derived: sum of 2 quarters · filed 2015-11-05
$19.02M
10-Q · filed 2015-11-05
$24.32M
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30$5.80M
10-Q · filed 2015-08-06
$10.55M
10-Q · filed 2015-08-06
$15.85M
derived: sum of 3 quarters · filed 2016-03-15
$20.34M
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31$4.76M
10-Q · filed 2015-05-06
$10.06M
derived: sum of 2 quarters · filed 2016-03-15
$14.54M
derived: sum of 3 quarters · filed 2016-03-15
$18.52M
derived: sum of 4 quarters · filed 2016-03-15
2013-12-31$5.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$9.78M
derived: sum of 2 quarters · filed 2016-03-15
$13.76M
derived: sum of 3 quarters · filed 2016-03-15
$16.92M
10-K · filed 2016-03-15
2013-09-30$4.49M
10-Q · filed 2014-10-30
$8.46M
derived: sum of 2 quarters · filed 2014-10-30
$11.62M
10-Q · filed 2014-10-30
$14.58M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30$3.97M
10-Q · filed 2014-08-07
$7.13M
10-Q · filed 2014-08-07
$10.09M
derived: sum of 3 quarters · filed 2015-03-02
$12.92M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31$3.16M
10-Q · filed 2014-05-08
$6.12M
derived: sum of 2 quarters · filed 2015-03-02
$8.95M
derived: sum of 3 quarters · filed 2015-03-02
$11.67M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31$2.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$5.79M
derived: sum of 2 quarters · filed 2015-03-02
$8.50M
derived: sum of 3 quarters · filed 2015-03-02
$10.45M
10-K · filed 2015-03-02
2012-09-30$2.83M
10-Q · filed 2013-11-07
$5.54M
derived: sum of 2 quarters · filed 2013-11-07
$7.49M
10-Q · filed 2013-11-07
$9.55M
derived: sum of 4 quarters · filed 2013-11-07
2012-06-30$2.71M
10-Q · filed 2013-08-08
$4.66M
10-Q · filed 2013-08-08
$6.73M
derived: sum of 3 quarters · filed 2013-08-08
$8.27M
derived: sum of 4 quarters · filed 2013-08-08
2012-03-31$1.95M
10-Q · filed 2013-05-09
$2.71M
10-Q · filed 2012-05-11
$4.01M
derived: sum of 2 quarters · filed 2013-05-09
$5.55M
derived: sum of 3 quarters · filed 2013-05-09
$7.14M
derived: sum of 4 quarters · filed 2013-05-09
2011-12-31$2.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11
$3.60M
derived: sum of 2 quarters · filed 2013-03-11
$5.20M
derived: sum of 3 quarters · filed 2013-03-11
$7.72M
10-K · filed 2013-03-11
$11.00M
10-K · filed 2012-03-20
2011-09-30$1.54M
10-Q · filed 2012-11-13
$2.48M
10-Q · filed 2011-11-10
$3.13M
derived: sum of 2 quarters · filed 2012-11-13
$5.66M
10-Q · filed 2012-11-13
$7.77M
10-Q · filed 2011-11-10
$6.78M
derived: sum of 4 quarters · filed 2012-11-13
2011-06-30$1.59M
10-Q · filed 2012-08-14
$2.37M
10-Q · filed 2011-08-12
$4.12M
10-Q · filed 2012-08-14
$5.28M
10-Q · filed 2011-08-12
$5.24M
derived: sum of 3 quarters · filed 2012-08-15
$6.92M
derived: sum of 4 quarters · filed 2012-08-15
2011-03-31$2.76M
10-Q · filed 2012-05-11
$3.65M
derived: sum of 2 quarters · filed 2012-08-15
$5.33M
derived: sum of 3 quarters · filed 2012-08-15
$7.46M
derived: sum of 4 quarters · filed 2012-08-15
2010-12-31$894.80K
derived: 8-K 12 month − 10-Q 9 month · filed 2012-08-15
$2.57M
derived: sum of 2 quarters · filed 2012-08-15
$4.71M
derived: sum of 3 quarters · filed 2012-08-15
$6.01M
8-K · filed 2012-08-15
$7.68M
10-K · filed 2012-03-20
2010-09-30$1.68M
10-Q · filed 2011-11-10
$3.81M
derived: sum of 2 quarters · filed 2011-11-10
$5.11M
10-Q · filed 2011-11-10
2010-06-30$2.13M
10-Q · filed 2011-08-12
$3.43M
10-Q · filed 2011-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
BIOVIE INC. (BIVI)United States$0.012B